Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Cash & Current Investments: 2018-2025

  • China SXT Pharmaceuticals' Cash & Current Investments rose 50.37% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 2.64%. This contributed to the annual value of $18.1 million for FY2025, which is 50.11% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Cash & Current Investments stood at $18.2 million for Q3 2025, which was up 0.17% from $18.1 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Cash & Current Investments registered a high of $18.2 million during Q3 2025, and its lowest value of $12.1 million during Q1 2024.
  • Moreover, its 3-year median value for Cash & Current Investments was $17.4 million (2023), whereas its average is $15.9 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 83.68% in 2021, then crashed by 30.46% in 2024.
  • Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Cash & Current Investments stood at $13.4 million in 2021, then grew by 16.55% to $15.6 million in 2022, then increased by 11.55% to $17.4 million in 2023, then crashed by 30.46% to $12.1 million in 2024, then skyrocketed by 50.37% to $18.2 million in 2025.
  • Its Cash & Current Investments was $18.2 million in Q3 2025, compared to $18.1 million in Q1 2025 and $12.1 million in Q3 2024.